Immune checkpoint inhibitors (ICIs) represent a significant advance in cancer treatment, targeting molecules such as programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Here, PDCD1 is linked to cancer.